Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 401

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 401
---
 Inc. On August 21, 2024, the Company received a letter from Dunn Lambert LLC, the law firm representing Clinilabs, stating that a complaint had been filed in the Superior Court of New Jersey. The complaint concerns three unpaid invoices totaling $886,412.46, plus interest at a rate of 6%. On June 1, 2023, Clinilabs entered into a start -upagreement with NLS. On December 4, 2023, NLS received five credit notes and two invoices from Clinilabs pursuant to services performed by Clinilabs under the start -upagreement. Clinilabs demanded $793,112.46 from NLS for unpaid service fees. On October 10, 2024, the Company successfully settled the outstanding claim through a debt purchase agreement with an accredited investor, in consideration of $500,222.91 and 49,475 NLS Common Shares equal in value to $279,299.90, which effectively resolved the creditor claim. CoreRX, Inc. On December 11, 2023, NLS received a notice alleging several causes of action, including a failure to remit payment for services rendered by CoreRX. On December 11, 2023, NLS and CoreRX agreed to a structured payment plan in which NLS agreed to pay CoreRX a total amount of $1,007,700.50. On October 10, 2024, the Company successfully settled the outstanding claim through a debt purchase agreement with an accredited investor, in the amount of $511,835, which effectively resolved the creditor claim. Université de Lausanne On August 27, 2024, the Company received correspondence from Université de Lausanne, initiating the official “audience de conciliation” procedure, overseen by the ordinary civil court in Lausanne. The hearing was scheduled for October 9, 2024, at the Tribunal d’arrondissement de Lausanne. The complaint pertains to an unpaid invoice for research services amounting to $110,179, plus interest at a rate of 5%. At the hearing on October 9, 2024, Université de Lausanne was not open to discussing a potential settlement. The Company asserts that the services provided did not meet the required standard of care and intends to defend its position. On May 9, 2025, the Company filed a statement of defense and asserted a counterclaim in CHF 30